← back to search

Lili Yang

Army Medical University · CN
Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, and Ferroptosis and cancer prognosis.
h-index
31
citations
3,095
works
154
NIH funding
primary concept
email

Recent publications

Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity
STAR Protocols 2025cited by 4position: lastdoi
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer
International Journal of Biological Sciences 2024cited by 28position: middledoi
Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma
Cancer Gene Therapy 2023cited by 29position: lastdoi
The malignancy suppression and ferroptosis facilitation of BCL6 in gastric cancer mediated by FZD7 repression are strengthened by RNF180/RhoC pathway
Cell & Bioscience 2023cited by 21position: lastdoi
Alveolar Macrophages-Mediated Translocation of Intratracheally Delivered Perfluorocarbon Nanoparticles to Achieve Lung Cancer <sup>19</sup>F-MR Imaging
Nano Letters 2023cited by 9position: middledoi
c-Met-Targeting 19F MRI Nanoparticles with Ultralong Tumor Retention for Precisely Detecting Small or Ill-Defined Colorectal Liver Metastases
International Journal of Nanomedicine 2023cited by 9position: middledoi
ANP32B promotes colorectal cancer cell progression and reduces cell sensitivity to PRAP1 inhibitor through up-regulating HPF1
Heliyon 2023cited by 3position: firstdoi
Pulmonary Delivery of Theranostic Nanoclusters for Lung Cancer Ferroptosis with Enhanced Chemodynamic/Radiation Synergistic Therapy
Nano Letters 2022cited by 91position: middledoi
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
Clinical Lung Cancer 2022cited by 36position: middledoi
Magnetic Resonance/Infrared Dual-Modal Imaging-Guided Synergistic Photothermal/Photodynamic Therapy Nanoplatform Based on Cu1.96S-Gd@FA for Precision Cancer Theranostics
Journal of Colloid and Interface Science 2022cited by 19position: middledoi
Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC
Molecular Cancer 2022cited by 15position: middledoi
Precise Cancer Anti-acid Therapy Monitoring Using pH-Sensitive MnO<sub>2</sub>@BSA Nanoparticles by Magnetic Resonance Imaging
ACS Applied Materials & Interfaces 2021cited by 32position: middledoi
Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial–mesenchymal transition and stem-like reprogram
Aging 2021cited by 19position: middledoi
Randomized, Multicenter, Open-Label Trial of Autologous Cytokine-Induced Killer Cell Immunotherapy Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
SSRN Electronic Journal 2020cited by 0position: middledoi
Non‐viral gene delivery for cancer immunotherapy
The Journal of Gene Medicine 2019cited by 26position: middledoi
Extended structure-activity study of anilino quinazoline-based EGFR tyrosine kinase inhibitors and the 18F-FDGPET/CT imaging for monitoring the therapeutic efficacy in non-small cell lung cancer
2019cited by 2position: middle
A novel MDSC-induced PD-1 <sup>−</sup> PD-L1 <sup>+</sup> B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties
OncoImmunology 2017cited by 95position: middledoi
Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells
Frontiers in Immunology 2017cited by 94position: middledoi
Methylation status of the promoter region of the human frizzled 9 gene in acute myeloid leukemia
Molecular Medicine Reports 2016cited by 12position: middledoi
Acute ethanol induces apoptosis by stimulating TRPC6 via elevation of superoxide in oxygenated podocytes
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2015cited by 9position: middledoi
Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2014cited by 42position: middledoi
Cholesterol inhibits ROMK channels by holding PI(4,5)P <sub>2</sub> in microvilli (1181.17)
The FASEB Journal 2014cited by 0position: middledoi
MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma
BMC Cancer 2012cited by 166position: middledoi
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome
The Journal of Immunology 2012cited by 83position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Xilin Sun · Fudan University7 papers (2019–2023)Kai Wang · Anyang Hospital of Traditional Chinese Medicine6 papers (2019–2023)Jie Yang · Harbin Medical University5 papers (2021–2023)Lina Wu · Guangzhou University of Chinese Medicine5 papers (2022–2023)Hongyan Zou · Allen Institute for Brain Science4 papers (2022–2023)Douglas C. Eaton · Emory University3 papers (2014–2015)Feng Wei · Hebei Medical University3 papers (2017–2021)He‐Ping Ma · Emory University3 papers (2014–2015)Jiannan Wang · Ministry of Education of the People's Republic of China2 papers (2022–2023)Xiaoyu Lu · Central South University of Forestry and Technology2 papers (2014–2015)Wenwen Yu · Nanjing Agricultural University2 papers (2017–2021)A Rong · Harbin Medical University2 papers (2021–2023)Yingbo Li · Harbin Medical University2 papers (2022–2023)Jian Wang · The First People's Hospital of Guiyang2 papers (2017–2017)Xiubao Ren · Tianjin Medical University Cancer Institute and Hospital2 papers (2017–2021)Xuesong Hu · Harbin Medical University2 papers (2021–2023) · 2 papers (2017–2021)Baozhong Shen · Harbin Medical University2 papers (2014–2014)Yingbo Li · Harbin Medical University2 papers (2021–2023)Bingchen Liu · Nanchang University2 papers (2014–2015)